Yukon Wealth Management Inc. Invests $741,000 in Johnson & Johnson (NYSE:JNJ)

Yukon Wealth Management Inc. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,470 shares of the company's stock, valued at approximately $741,000.

A number of other large investors also recently modified their holdings of JNJ. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC grew its holdings in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after purchasing an additional 1,022 shares during the period. Bedel Financial Consulting Inc. raised its stake in Johnson & Johnson by 7.0% in the 4th quarter. Bedel Financial Consulting Inc. now owns 14,878 shares of the company's stock valued at $2,301,000 after acquiring an additional 973 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 3.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 18,187,082 shares of the company's stock valued at $2,630,216,000 after buying an additional 547,714 shares in the last quarter. Finally, Bahl & Gaynor Inc. grew its position in shares of Johnson & Johnson by 303.0% in the fourth quarter. Bahl & Gaynor Inc. now owns 1,328,414 shares of the company's stock valued at $192,115,000 after purchasing an additional 998,761 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on JNJ. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Barclays lowered their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Finally, Morgan Stanley boosted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Stock Up 0.2%

Shares of NYSE JNJ traded up $0.34 during midday trading on Friday, hitting $155.90. The stock had a trading volume of 3,482,521 shares, compared to its average volume of 8,047,072. The company has a market cap of $375.11 billion, a P/E ratio of 17.34, a PEG ratio of 2.35 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The business's 50 day moving average is $153.65 and its 200-day moving average is $153.96. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.